Tumor Biology

, Volume 36, Issue 9, pp 7277–7283 | Cite as

RETRACTED ARTICLE: MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL

  • Rui Li
  • Xuejun Shi
  • Fengyu Ling
  • Chunguang Wang
  • Junxia Liu
  • Wei Wang
  • Ming Li
Research Article


Increasing evidence has suggested that dysregulation of microRNAs (miRNAs) could contribute to tumor progression. The miR-34 family is directly transactivated by tumor suppressor p53 which is frequently mutated in various cancers; however, the effect of miR-34a on the ovarian cancer cells remains unclear. The aim of the paper was to study the expression of miR-34a in ovarian cancer and miR-34a’s relation to the cell proliferation and metastasis in ovarian cancer in vitro. miR-34a expression was determined by quantitative RT-PCR in a panel of 60 human ovarian cancer samples. Functional characterization of miR-34a was accomplished by reconstitution of miR-34a expression in ovarian cancer cells by determining changes in proliferation, migration, and invasion. Our results showed that miR-34a is downregulated in ovarian cancer tissues compared with the corresponding adjacent non-neoplastic tissues, and the expression level of miR-34a was significantly lower in ovarian cancer cell lines in comparison with normal human fallopian tube epithelial cell line. The 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-diphenytetrazoliumromide (MTT) assay revealed significant cell proliferation inhibition in miR-34a transfectant compared with the control from HO8910 and SKOV3 cells, which displayed lowest expressions of miR-34a. Furthermore, the transwell assay also showed significant cell migration inhibition in miR-34a transfectant, compared with cell lines transfected with NC. Overexpression of miR-34a led to the inhibition of AXL expression, indicating that AXL is a target gene for miR-34a. Our data suggest that miR-34a may function as a tumor suppressor through repression of oncogenic AXL in ovarian cancer.


Ovarian cancer MiR-34a AXL P53 Proliferation Migration 



This study was supported by the grants from the medical research project of Chongqing Municipal Health Bureau (No. 2012-2-159)

Conflicts of interest



  1. 1.
    Brouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y, Huang GS. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PLoS One. 2014;9(6):e100165.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012;13:271–82.PubMedGoogle Scholar
  5. 5.
    Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113:673–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  7. 7.
    Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27(3):443–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Chen WY, Liu SY, Chang YS, Yin JJ, Yeh HL, Mouhieddine TH, et al. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget. 2015;6(1):441–57.PubMedGoogle Scholar
  9. 9.
    Xiao X, Chen B, Liu X, Liu P, Zheng G, Ye F, et al. Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One. 2014;9(11), e112720.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Li X, Zhao H, Zhou X, Song L. Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. Mol Med Rep. 2015;11(1):577–82.PubMedGoogle Scholar
  11. 11.
    Wu MY, Fu J, Xiao X, Wu J, Wu RC. MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett. 2014;354(2):311–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Suh YA, Jo SY, Lee HY, Lee C. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int J Oncol. 2015;46(3):1405–11.PubMedGoogle Scholar
  13. 13.
    Concepcion CP, Han Y-C, Mu P, Bonetti C, Yao E, D’andrea A, et al. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet. 2012;8, e1002797.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Liu N, Landreh M, Cao K, Abe M, Hendriks G-J, Kennerdell JR, et al. The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila. Nature. 2012;482:519–23.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298–307.CrossRefPubMedGoogle Scholar
  17. 17.
    Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM, Chan WY. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer. 2010;102:419–27.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68:4123–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011;30:2888–99.CrossRefPubMedGoogle Scholar
  21. 21.
    Hafizi S, Dahlback B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 2006;273:5231–44.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Rui Li
    • 1
  • Xuejun Shi
    • 1
  • Fengyu Ling
    • 1
  • Chunguang Wang
    • 1
  • Junxia Liu
    • 1
  • Wei Wang
    • 1
  • Ming Li
    • 1
  1. 1.Department of OncologyYongchuan Hospital Affiliated to Chongqing Medical UniversityChongqingChina

Personalised recommendations